Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Wellness Network.
Press releases published on June 26, 2025
Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations
GlobeNewswire
·
June 26, 2025
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare …
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
GlobeNewswire
·
June 26, 2025
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and …
XORTX Announces USD $925,000 Private Placement
GlobeNewswire
·
June 26, 2025
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 26, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late …
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
GlobeNewswire
·
June 26, 2025
Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA® at medical conferences and a planned KOL event MDNA11 …
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
GlobeNewswire
·
June 26, 2025
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis …
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
GlobeNewswire
·
June 26, 2025
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile- -Complete …
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
GlobeNewswire
·
June 26, 2025
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the study No evidence …
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
GlobeNewswire
·
June 26, 2025
ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target ProFound to leverage its ProFoundry™ Platform to mine the expanded proteome to identify previously unknown proteins …
I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
GlobeNewswire
·
June 26, 2025
71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Updated …
World No. 1 Tennis Star Aryna Sabalenka Joins Prenetics’ IM8 Health as Global Ambassador and Shareholder
GlobeNewswire
·
June 26, 2025
Aryna Sabalenka becomes first-ever current athlete shareholder in Prenetics, listed on the NASDAQ: (PRE) In just six months, IM8 is one of the fastest growing supplement brands in the world, generating an extraordinary US$50m+ Annual Recurring Revenue IM8 …
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
GlobeNewswire
·
June 26, 2025
REYKJAVIK, Iceland, June 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its lenders under …
26 ZAZA THCA Flower Strains Unleashed: The Hemp Doctor’s Largest Drop Yet
GlobeNewswire
·
June 26, 2025
MOORESVILLE, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, America’s premier hemp and cannabinoid brand, introduces its largest THCA flower collection release with 26 indoor-grown unique strains handpicked for exceptional quality, flavor, and …
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
GlobeNewswire
·
June 26, 2025
Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza vaccine companies, for the marketing and …
Valneva annonce un accord exclusif avec CSL Seqirus pour le marketing et la distribution de ses vaccins en Allemagne
GlobeNewswire
·
June 26, 2025
Saint-Herblain, France, le 26 juin 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui un accord exclusif avec CSL Seqirus, l'une des plus grandes entreprises de vaccins antigrippaux au …
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
GlobeNewswire
·
June 26, 2025
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from …
Electronic Health Records (EHR) Market Valued at USD 33.45 Billion in 2024, Set to Grow at 4.59% CAGR Through 2032 | AnalystView Market Insights
GlobeNewswire
·
June 26, 2025
San Francisco, USA, June 25, 2025 (GLOBE NEWSWIRE) -- The Electronic Health Records (EHR) market was valued at USD 33,451.20 million in 2024 and is projected to grow at a CAGR of 4.59% from 2025 to 2032. This growth is driven by the global shift toward …